Alnylam

Press Releases

May 08,2018
Summary ToggleAlnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
PDF Version
May 03,2018
Summary ToggleAlnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
PDF Version
May 03,2018
Summary ToggleAlnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
PDF Version
May 01,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming May Investor Conferences
PDF Version
Apr 26,2018
Summary ToggleAlnylam to Webcast Conference Call Discussing First Quarter 2018 Financial Results
PDF Version
Apr 24,2018
Summary ToggleAlnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting
PDF Version
Apr 23,2018
Summary ToggleAlnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
PDF Version
Apr 20,2018
Summary ToggleAlnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation
PDF Version
Apr 14,2018
Summary ToggleAlnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
PDF Version
Mar 28,2018
Summary ToggleAlnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)
PDF Version
Mar 28,2018
Summary ToggleAlnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
PDF Version
Mar 26,2018
Summary ToggleAlnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Mar 21,2018
Summary ToggleRegeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)
PDF Version
Mar 21,2018
Summary ToggleAlnylam to Webcast Presentation at 17th Annual Needham Healthcare Conference
PDF Version
Mar 14,2018
Summary ToggleAlnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
PDF Version
Mar 13,2018
Summary ToggleAlnylam Unveils Resources to ‘Bridge the Gap’ in Knowledge of Hereditary ATTR (hATTR) Amyloidosis Among Families at Risk
PDF Version
Mar 12,2018
Summary ToggleAlnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Mar 06,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming March Investor Conferences
PDF Version
Feb 08,2018
Summary ToggleAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
PDF Version
Feb 05,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming February Investor Conferences
PDF Version
Displaying 21 - 40 of 970 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More